<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001081'>Cholelithiasis</z:hpo> has been reported with a variable incidence in <z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">homozygous beta-thalassaemia</z:e>, the reasons for which have only partially been defined </plain></SENT>
<SENT sid="1" pm="."><plain>Disease-associated factors or specific modifier genes may be implicated </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed the prevalence of <z:hpo ids='HP_0001081'>cholelithiasis</z:hpo> and the effect of co-inherited <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> genotype on its development in 261 thalassaemia major (TM) and 35 thalassaemia intermedia (TI) patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001081'>Cholelithiasis</z:hpo> was found in 20.3% of TM and in 57.1% of TI patients </plain></SENT>
<SENT sid="4" pm="."><plain>Its incidence was higher (P &lt; 0.05) in patients homozygous for the (TA7) motif in the promoter of the UGT1-A1 gene, the genotype associated with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>, which seems to be a risk factor for the development of <z:hpo ids='HP_0001081'>gallstones</z:hpo> in TM and TI patients </plain></SENT>
</text></document>